Autobahn Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Audio By Carbonatix

SAN DIEGO--(BUSINESS WIRE)--Dec 17, 2025--

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT in San Francisco.

About Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by elunetirom (ABX-002), a CNS thyroid hormone receptor (CNS-TR) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251217764141/en/

CONTACT: Investors:

Alex Straus

THRUST Strategic Communications

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: MENTAL HEALTH HEALTH NEUROLOGY GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Autobahn Therapeutics

Copyright Business Wire 2025.

PUB: 12/17/2025 08:00 AM/DISC: 12/17/2025 08:00 AM

http://www.businesswire.com/news/home/20251217764141/en